Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients

被引：0
|
作者：
Diana Carmona-Fernandes
Maria José Santos
Inês Pedro Perpétuo
João Eurico Fonseca
Helena Canhão
机构：
[1] Instituto de Medicina Molecular,Rheumatology Research Unit
[2] Faculdade de Medicina da Universidade de Lisboa,Rheumatology Department
[3] Edifício Egas Moniz,Rheumatology and Bone Metabolic Diseases Department
[4] Hospital Garcia de Orta,undefined
[5] Hospital de Santa Maria,undefined
来源：
Arthritis Research & Therapy | / 13卷
关键词：
sRANKL; osteoprotegerin; systemic lupus erythematosus; osteoclastogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Osteoprotegerin-receptor activator of nuclear factor-κB ligand ratio:: A new approach to osteoporosis treatment?
    Coetzee, M
    Kruger, MC
    SOUTHERN MEDICAL JOURNAL, 2004, 97 (05) : 506 - 511
  • [22] Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma:: proposal for a novel prognostic index
    Terpos, E
    Szydio, R
    Apperley, JF
    Hatjiharissi, A
    Politou, M
    Meletis, J
    Viniou, N
    Yataganas, X
    Goldman, JM
    Rahemtulla, A
    BLOOD, 2003, 102 (03) : 1064 - 1069
  • [23] Assessment of receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in lymphoma patients
    Ayoub, M.
    Gadallah, H.
    Hegab, H.
    Khattab, D.
    Mostafa, N.
    EJC SUPPLEMENTS, 2010, 8 (04): : 22 - 22
  • [24] Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment
    Bayer, Christian M.
    Beckmann, Matthias W.
    Fasching, Peter A.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2017, 29 (01) : 4 - 11
  • [25] Receptor activator of nuclear factor κB ligand and osteoprotegerin regulate aortic valve calcification
    Kaden, JJ
    Bickelhaupt, S
    Grobholz, R
    Haase, KK
    Sartkoç, A
    Kiliç, R
    Brueckmann, M
    Lang, S
    Zahn, I
    Vahl, C
    Hagl, S
    Dempfle, CE
    Borggrefe, M
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (01) : 57 - 66
  • [26] Osteoprotegerin to soluble receptor activator of nuclear factor κ-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3
    Voskaridou, E
    Terpos, E
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 74 (04) : 359 - 361
  • [27] Effects of High and Low Doses of Folic Acid on the Soluble Receptor Activator of Nuclear Factor-kappa B Ligand/Osteoprotegerin Ratio during Pregnancy
    Fathi Maroufi, Nazila
    Ghorbanihaghjo, Amir
    Melli, Manizheh Sayyah
    Vaezi, Maryam
    Hekmati Azar Mehrabani, Zohreh
    Bannazadeh Amirkhiz, Maryam
    Rashtchizadeh, Nadereh
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2017, 46 (04) : 517 - 524
  • [28] Platelet-rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio in osteoblasts
    Sumida, Ryuta
    Maeda, Toyonobu
    Kawahara, Ichiro
    Yusa, Junko
    Kato, Yasumasa
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (01) : 358 - 365
  • [29] Prolactin decreases the expression ratio of receptor activator of nuclear factor κB ligand/osteoprotegerin in human fetal osteoblast cells
    Seriwatanachai, Dutmanee
    Charoenphandhu, Narattaphol
    Suthiphongchai, Tuangporn
    Krishnamra, Nateetip
    CELL BIOLOGY INTERNATIONAL, 2008, 32 (09) : 1126 - 1135
  • [30] The Role of the Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Vascular Diseases: A Therapeutic Approach
    Celebi Torabfam, Gizem
    Porsuk, Melis Hazal
    ANGIOLOGY, 2024,
12345